Souvien Therapeutics

Souvien Therapeutics is a private biotechnology company within the Juvenescence portfolio focused on developing therapeutics for neurodegenerative disease. The company was launched in 2019 around research from Li-Huei Tsai at MIT and Stephen Haggarty at Harvard Medical School/Massachusetts General Hospital on the epigenetic basis of neurodegeneration. Public descriptions indicate that Souvien is pursuing novel agents that modulate critical epigenetic mechanisms, with later Juvenescence materials specifically referencing HDAC activators for neurodegenerative and inflammatory diseases. No clinical-stage assets or named human trial programs were identified in the available public sources, so the company appears to remain preclinical. Souvien is best understood as an early-stage neurodegeneration-focused biotech backed by Juvenescence and rooted in academic translational science.